Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.
The firm’s shares popped after the FDA granted accelerated approval for its Wegovy drug to treat adults with moderate to advanced liver fibrosis. Trading near 52-week lows, the Copenhagen-based pharma giant now finds itself in a prime position for a potential rebound. Investors are taking notice of both the regulatory win and favorable technical signals.
